Edding Genor Group Holdings Limited (HKG:6998)

Market Cap	5.22B
Revenue (ttm)	n/a +1,448.1%
Net Income	n/a
EPS	n/a
Shares Out	2.00B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,000
Average Volume	1,202,999
Open	2.610
Previous Close	2.610
Day's Range	2.610 - 2.800
52-Week Range	1.710 - 5.600
Beta	0.95
RSI	49.18
Earnings Date	Mar 27, 2026

About HKG:6998

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are in preclinical and early clinical stages. It also provides Van...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6998

Financial Performance

Financial numbers in CNY